NCT02015091View on ClinicalTrials.gov

Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

141

Participants

Timeline

Start Date

December 12, 2013

Primary Completion Date

May 1, 2015

Study Completion Date

September 8, 2016

Conditions

Malaria

Interventions

BIOLOGICAL

PfSPZ Vaccine

The PfSPZ Vaccine is composed of radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) and is designed to prevent malaria in adults, children, and infants. It is formulated in phosphate buffered saline (PBS) with 1% human serum albumin (HSA). Sanaria Incorporated (Sanaria), Rockville, Maryland, developed and produced the PfSPZ Vaccine.

Trial Locations (2)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

21201-1595

University of Maryland Center for Vaccine Dev, Baltimore, Baltimore

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02015091 - Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults | Biotech Hunter | Biotech Hunter